217 related articles for article (PubMed ID: 26250968)
21. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
23. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.
Togami S; Sasajima Y; Oi T; Ishikawa M; Onda T; Ikeda S; Kato T; Tsuda H; Kasamatsu T
Cancer Sci; 2012 May; 103(5):926-32. PubMed ID: 22329832
[TBL] [Abstract][Full Text] [Related]
25. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
27. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
28. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
30. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
31. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
32. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
33. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
34. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
35. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
[TBL] [Abstract][Full Text] [Related]
36. Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors?
Dasanu CA; Lerner J; Ocampo MM; Iskandar AS; Kaur J; Tuler S; Codreanu I; Farrell S; Plaxe SC
J Oncol Pharm Pract; 2021 Jul; 27(5):1181-1185. PubMed ID: 33983075
[TBL] [Abstract][Full Text] [Related]
37. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
38. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
39. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
40. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation.
Singh P; Smith CL; Cheetham G; Dodd TJ; Davy ML
Int J Gynecol Cancer; 2008; 18(6):1344-51. PubMed ID: 18248390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
